Resources & Publications
The Lankenau Institute for Medical Research
Wynnewood, Pennsylvania
Wynnewood, Pennsylvania
Resources & Publications
Wynnewood, Pennsylvania
Animal: The Lankenau Institute for Medical Research has a Central Animal Facility accredited by AAALAC. The transgenic and knockout mice used in this project have been generated and well characterized in the preliminary studies.
The Proteomics Facility used for the preliminary studies is located at the Wistar Institute and accessible by user fees. This Facility consists of multiple sections, for protein sequencing, amino acid analysis, protein/peptide purification by HPLC or electrophoretic techniques (e.g. electro blotting), peptide synthesis, and mass spectrometry. Other facilities are located at the Lankenau Institute for Medical Research (LIMR) and include Bio imaging, Biostatistics, Cytogenetics, Flow Cytometry, Pathology, and X-Ray Crystallography and other facilities located at the Wistar Institute. The services of the facilities are provided on a charge-back basis. All the LIMR facilities are located on the same floor or within two floors from Dr. Pestell's laboratory in the same building. The administrative office for LIMR is located on the floor below the PI’s office. There is a conference room and library that contains key journals. The transgenic mice are housed on the same floor as the laboratory providing easy access for the proposed experiments. The laboratories are well equipped for molecular biology experiments. The investigators of LIMR, the Blumberg Institute and the Wistar Institute, are focused on cancer research and represent a substantial collective group of approximately funded laboratories. Many laboratories are actively involved in studies of transcriptional control, innovative transgenic mouse modeling and translational research initiatives. This Institution provides a rich research environment that fosters the exchange of ideas and provides a number of relevant seminars, symposia, and journal clubs.
LIMR (affiliated with Thomas Jefferson University) is a state-of-the-art research facility located in a modern, 53,000-square-foot three-story building contiguous with the Lankenau Medical Center, which contains a 320-bed tertiary care teaching hospital in Wynnewood, PA. LIMR and the Medical Center have a vibrant Infectious Disease group. All equipment required for the project is available at LIMR.
Laboratories: Within LIMR are sixteen 1,137-square-foot laboratories located on the perimeter of the first and second floors that are designed and equipped to support research utilizing the latest molecular and biochemical techniques. All laboratories are equipped with at least one fume hood and one to two laminar flow hoods serviced with vacuum and gas. CO2 incubators are supplied by a central CO2 generating system located in the loading dock adjacent to the ground floor. All the laboratories are well equipped with basic equipment necessary to perform molecular and biochemical techniques, including micro-centrifuges, balances, shakers, water baths, SDS PAGE equipment, transblot apparatus, agarose gel electrophoresis equipment, PCR machines, real time qPCR, power supplies, gel dryers, pH meters, warm/stir plates, vortexes, a variety of pipeting devices, lyophilizers, rotoevaporators, ultrafiltration apparatus, 4 hybridization ovens, deli-style refrigerators, microwaves, ELISA plate readers, and spectroflurometers. Low temperature freezers are in a central location as are liquid nitrogen storage units supported from a central tank.
Major Equipment: LIMR has all the equipments required to run the proposed project. The Institute has an assortment of microscopes for performing dark phase and light field and fluorescent microscopy, including 3 Wild M3Z dissecting microscopes, a Leitz Labovert inverted compound microscope and a Nikon Diaphot inverted compound microscope, which are both equipped with micromanipulators, Axioplan and IMT-2 photomicroscopes, a Zeiss Axioplan Phase Contrast Fluorescent microscope, a Zeiss Axioscop 20 Fluorescent microscope equipped with a Optronics DEI 750 video camera and a Video Sony UP-D 5600MD printer, an Olympus BX60 fluorescent/brightfield microscope dedicated for image analysis, an Olympus BH2 fluorescent/bright field microscope with fully automated Prior stage for cell counting, a Canon BX60 fluorescent microscope, a Nikon SMZ1500 fluorescent dissecting microscope and Nikon Confocal microscope. Available on a shared basis are a Varian HPLC system equipped with a IN/US bRAM Model 2 flow-through detector, Vickers M-85 scanning densitometer, Speed-Vac, Bio-Rad Gene Pulser with capacitance extender for electroporation of eukaryotic cells, a BioMag Magnetic separator for magnetic cell sorting, a Turner Model 20e luminometer, and 2 Coulter counters. In addition to the basic laboratory equipment, a central service laboratory has a BD FACSCanto II flow cytometer containing 488nm solid state and 633nm HeNe lasers with 6-color capability, two Cruachem oligonucleotide synthesizers, two ABI Prism 310 Genetic Analyzer for automatic DNA sequence analysis, 3 Bio-Rad DNA sequencing apparatus, ABI Prism 7700 Sequence Detector, and a Molecular Dynamics Phosphoimager/ Densitometer. The Institute also has Biotek ELISA readers. The instruments are available to the entire scientific staff.
Spacious scientific support areas (1005 ft2) are designed into the central core area on each floor: The central glasswash area equipped with three automatic washers, a Getinge/Castle Biohoe autoclave, and two large capacity forced air ovens is located in the core of the ground floor. Installed in the central glasswash is a constant re-circulating high purity reverse osmosis water system (Culligan) that supplies 18 megohm water and steam to the washers and autoclave, respectively. A full-time glasswash technician is employed by the Institute to operate this facility. Common rooms for equipment shared by the entire scientific staff are located on the first and second floor central core areas where there are 4 Beckman Optima ultra-high speed centrifuges, 4 Sorval plus 1 Beckman high speed centrifuges, 3 Packard liquid scintillation counters, 1 Packard Cobra gamma counter, 2 Virtis freeze dryers, 2 Scotsman ice machines, a Gilford 2600 recording spectrometer, a Beckman DU 7500 UV/visible spectrophotometer, 2 floor mounted environmental shakers, a Branson ultrasonic cell disrupter, and in each common service area, a Culligan recirculating water system that supplies the laboratories with high purity water as well as the source of high purity steam for the Getinge/Castle Biohoe autoclave on each floor. A refrigerator/freezer room adjoins the common equipment room on each floor. On each of these floors is a dark room equipped with a copy stand, UV light box, and a film processor (Kodak Xomat in one of the dark rooms and a Konica XRX in the other) and a BioRad
Chemidoc for gel and blot documentation and analysis. In addition, a walk-in cold room and warm room are located adjacent to the common equipment room on both of these floors. A Histology Laboratory, Liquid Nitrogen Freezer Room, mechanical space and a Storage Room are located on the perimeter of the Ground floor. A fully equipped histology laboratory is equipped with a RMC tissue processor, 2 Leica/Reichert microtomes and 1 Bright Instruments Cryo-microtome.
In the Liquid Nitrogen Freezer Room, five liquid nitrogen freezers are attached to a manifold system specially designed to monitor and maintain a safe level of liquid nitrogen in each freezer. In addition to liquid nitrogen freezers, this room can accommodate -200C and -800C freezers. A large liquid nitrogen tank is located exterior to the Freezer Room as the source. Also located on the ground floor is a room specifically designed to safely operate a J. L. Shepherd Mark I, Model 68A Cesium Irradiator.
LIMR has a number of Cores in place to support the research programs of all investigators. The Cores include a Histology Core, which prepares and sections frozen and paraffin embedded tissues,; an Imaging Core to analyze microscopic specimens; and a Transgenic Mouse Core, which generates mutant mice. LIMR investigators also have access to the core facilities at Thomas Jefferson University, Wistar Institute and University of Pennsylvania.
Learn More about LIMR: http://www.limr.org/
WEBSITES RELEVANT TO TRANSGENIC STUDIES:
Non-murine transgenics:
Genome Technology Core (formerly MIT/Whitehead Center for Genome Research): https://wi.mit.edu/core-facilities/genomecore
Agrigenomics Information database; Animal Genome Database: https://agrid.dna.affrc.go.jp/index.php?page=animal_db&lang=en
Flybase (D. melanogaster): https://flybase.org/
The Zebrafish Information Network (ZFIN): https://zfin.org/
Yeast Genome Database (S. cerevisiae): https://www.yeastgenome.org/
Murine Transgenics:
The Jackson Laboratory (JAX): https://www.jax.org/
Mouse Genome Informatics: https://www.informatics.jax.org/
eMouseAtlas: https://www.emouseatlas.org/emap/home.html
The Whole Mouse Catalog: https://norecopa.no/norina/the-whole-mouse-catalog/
Knockouts:
Knockout Mouse Project: https://www.jax.org/research-and-faculty/resources/knockout-mouse-project
Cre Transgenic database: http://www.mshri.on.ca/nagy/
Crossing Organisms:
National Center for Biotechnology Information: http://www.ncbi.nlm.nih.gov/index.html
Genbank: https://www.ncbi.nlm.nih.gov/genbank/
OMIM – Online Mendelian Inheritance in Man (Human Genes & Genetic Disorders): https://www.ncbi.nlm.nih.gov/omim
Mapping and Sequencing:
National Center for Genome Resources: https://www.ncgr.org/
Laboratory of Statistical Genetics: https://lab.rockefeller.edu/ott/
Stanford Genome Technology Center: https://med.stanford.edu/sgtc/general/history.html
Genethon: French Gene Therapy Research and Genomic Center: https://www.genethon.com/
To Know More, Visit:
https://www.youtube.com/channel/UCxvxtNG-ZsBe0F8RJGI4W8Q
https://en.wikipedia.org/wiki/Richard_Pestell
https://www.pcarmrc.org/pestell-1
https://blumberginstitute.org/faculty/richard-g-pestell/
https://www.linkedin.com/in/richard-pestell-aa869352
https://www.cytodyn.com/newsroom/detail/632/cytodyn-appoints-richard-pestell-m-d-ph-d-as-lead
https://scholar.google.com/citations?user=6icYuFsAAAAJ
https://www.seakexperts.com/members/8904-richard-g-pestell
https://data.the-asci.org/controllers/asci/DirectoryController.php?action=profile&entryId=500154
https://research-repository.uwa.edu.au/en/persons/richard-pestell/
https://blumberginstitute.org/faculty-news-blumberg-institute-scientist-receives-2-6-million-grant-from-the-research-grant-hungary-program/
https://www.hepb.org/news-and-events/news-2/dr-richard-g-pestell-joins-the-baruch-s-blumberg-institute/
https://finance.yahoo.com/news/cytodyn-appoints-richard-pestell-m-133000105.html
https://www.healthgrades.com/physician/dr-richard-pestell-x59j3
https://www.youtube.com/channel/UCxvxtNG-ZsBe0F8RJGI4W8Q
https://www.facebook.com/xavieruniversityaruba/posts/effective-june-30-2025-dr-richard-pestell-will-conclude-his-seven-years-of-disti/1093444219483164/
https://www.nasdaq.com/articles/cytodyn-names-richard-pestell-lead-consultant-oncology-drive-leronlimab-progress
https://orcid.org/0000-0003-3244-8777
https://councils.forbes.com/profile/Richard-Pestell-CEO-Founder-Stroma-Genesis/0ac92362-5f97-4c83-a953-d4363d179880
https://www.ae-info.org/ae/Member/Pestell_Richard/CV
https://mdhs.unimelb.edu.au/engage/community/awards-and-honours/richard-george-pestell
https://www.pcarmrc.org/international-members-1
https://www.ae-info.org/ae/Member/Pestell_Richard
https://www.sbs.com.au/news/article/biotechnology-award-dr-richard-pestell/womarpd5d
https://www.pcarmrc.org/what-we-do
https://blumberginstitute.org/faculty-news-blumberg-institute-scientist-receives-2-6-million-grant-from-the-research-grant-hungary-program/
https://finance.yahoo.com/news/cytodyn-appoints-richard-pestell-m-133000105.html
https://www.hepb.org/news-and-events/news-2/dr-richard-g-pestell-joins-the-baruch-s-blumberg-institute/
https://research-repository.uwa.edu.au/en/persons/richard-pestell/
https://mta.hu/english/members-elected-to-the-hungarian-academy-of-sciences-in-2025-114411
https://hun-ren.hu/research_news/the-institute-of-molecular-life-sciences-celebrates-its-75th-anniversary-with-leading-national-and-international-researchers-108830
https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=
https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fearly-cancer-trauma-inspired-lifes-work-for-richard-pestell%2Fnews-story%2F0fbb35ef2b079bcc9cab172a13a18713&memtype=anonymous&mode=premium&v21=GROUPA-Segment-1-NOSCORE&V21spcbehaviour=append
STATUS
Richard Pestell, AO, MD, PhD, MBA, MB, BS, FRACP, FACP, FRCP (Ireland), FRCP (London), MAE, is a clinician scientist, who currently serves as the President of the Pennsylvania Cancer and Regenerative Medicine Center, and Member of Wistar Institute Cancer Center (Associate), in Philadelphia, USA.
He was previously Executive Vice President Thomas Jefferson University, Philadelphia, USA (30,000 employees, $5.6B USD annual budget.
BACKGROUND
Dr. Pestell’s education was in medicine, cancer research and business. He received M.D. and Ph.D. degrees from Melbourne University, and his MBA from NYU, Stern School of Business. Dr. Pestell completed his M.B., BS at the University of Western Australia, and conducted clinical training in Internal Medicine, Oncology and Endocrinology. He was the Winthrop Fellow at Harvard Medical School and was Clinical Fellow at Massachusetts General Hospital.
He has received awards and elected memberships (~20) to academic societies for his research, clinical care, and impact on improving healthcare access. He was appointed as an Officer of the Order of Australia from Queen Elizabeth II (2019) for “distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology”. https://en.wikipedia.org/wiki/Richard_Pestell.
Other Elected Memberships include Academia Europaea, the American Society for Clinical Investigation. Awards include the RD Wright Medallion, The Eric Susman Prize in Medicine, Doctor of Medical Sciences, Honoris Causa, University of Melbourne, Doctor Honoris Causa, University of Western Australia
He previously and or currently served as a member of the Editorial Board of 14 journals, as a Reviewer of 18 funding agencies in 9 countries, and consults for domestic and international research organizations and governments including Hungary.
He has founded six biotechnology companies (LightSeed, Shenandoah, ioROC, StromaGenesis, ProstaGene, EcoGenome). He sold ProstaGene with a successful exit in 2018. His companies have been financed primarily through NIH funded research and private investors.
He has been the Principal Investigator of >$86mMM USD in grants primarily from the NIH, raised ~$50MM USD from investors for biotechnology company development, published more than 700 works with >99,000 citations, H index 159 and is ranked by Google Scholar #1 in the world for his area of science (“cell cycle”). He holds multiple issued patents in cancer diagnostics and treatment. Of 484 publications published 1996-2023, 161 have been cited in in 677 patents (SciVal). He has authored 1 book, 52 book chapters and delivered 294 invited lectures and 236 meeting presentations.
His research has led to the current use of new therapies. Dr. Pestell identified key genetic targets for cancer, including cyclins and CCR5.
(1) His preclinical studies of cyclin D1 in breast cancer were cited as the basis for the clinical trials of CDK inhibitors, now approved by the FDA for treatment of cancer.
(2) His preclinical studies of CCR5 inhibitors are cited as the basis for the current clinical trials of CCR5 inhibitors for cancer (3).
(3). His discovery that nuclear receptors are acetylated, thereby governing diverse functions, provided important insights into hormone signaling and cancer.
CONTRIBUTIONS TO SCIENCE
Prostate cancer: As prostate cancer onset and progression involves the mune system we developed a metastatic murine model that recapitulates human prostate cancer, both geneticaly and epigenetically, and metastasizes to bones and brain in the muse.. We demonstrated that in human prostate cancer cells the abundance of cyclin D1 is induced by growth factors and siRNA to cyclin D1 reduced ErbB2-mediated DNA synthesis in LNCaP cells (Cancer Research, 2007; 67(9):4364-4372)., that cyclin D1 restrains EMT and promotes stem cell expanding gene expression in the prostate. This may contribute to its strong prognostic value for poor outcome in biochemical-free recurrence in human prostate cancer (Cancer Research, 2014; Jan 15; 74(2):508-19).
Dach1 and Cancer. Dach1 was initially cloned as a gene governing eye development. Dr. Pestell has led in the field of Dach1 in tumorigenesis. Pestell was the first to show that Dach1 restrains tumor growth, that the abundance of Dach1 is reduced in human cancers and that Dach1 restrains stem cells through reprogramming an Oct/Nanog/EKLF pathway. He was the first to show Dach1 binds to non-canonical TF binding sites (c-Jun, Smad) and bind DNA directly to promote gene expression modules. He showed Dach1 is phosphorylated and acetylated and controls breast cancer epithelial cell growth and migration in vitro and in vivo.
Androgen and Nuclear receptor acetylation. Dr. Pestell was the first to show nuclear receptors including the androgen receptor, are acetylated, that acetylation regulates contact-independent growth, and that this event is rate-limiting in hormone signaling and that acetylation is a general mechanism conserved among diverse nuclear receptors regulating diverse biological processes. Dr. Pestell proved that a single residue acetylated in the nuclear receptor, converted a growth suppressor into a growth activator. There have been >19,300 publications on nuclear receptor acetylation since our original discovery.
Cancer Stem cells. The Pestell lab has defined the requirement for specific target genes in the formation of breast and prostate epithelial cancer stems cells using transgenic or inducible knockout mice (NFκB, p21CIP1, c-jun) and have defined distinct roles for cyclin D1 in polarity vs stem cell function. These transgenic animals have been shared widely with the research community.
Cyclin D1 non canonical functions governing gene expression. Dr. Pestell has been a pioneer in the understanding of cell-cycle control in cancer. He was the first to show that: 1) cyclins are direct transcriptional targets of oncogenic and tumor suppressor signals; 2) cyclin D1 expression is rate-limiting for oncogeneinduced breast tumor and colon growth in vivo; 3) cyclin D1 binds DNA to regulate gene expression and chromosomal instability; 4) cyclins interact with nuclear receptors and tumor suppressors; 5) cyclins regulate mitochondrial metabolism, cellular migration, the non-coding genome and its biogenesis.
Summary of Published Work (>615 published works with >99,000 citations):
https://pubmed.ncbi.nlm.nih.gov/?term=Pestell+R
https://scholar.google.com/citations?hl=en&user=6icYuFsAAAAJ&view_op=list_works&sortby=pubdate
SELECTED PUBLICATIONS
1. Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, Walters R, Fortina P, Lisanti MP, Pestell RG Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res. 2013 Jan 15;73(2):978-89. doi: 10.1158/0008-5472.CAN-12-2133. Epub 2012 Nov 30. PMCID: PMC3561759.
2. Ju, X. and Casimiro, M.C., Gormley, M., Meng, H., Jiao, X., Katiyar, S., Crosariol, M., Chen, K., Wang, M., Quong, A.A., Lisanti MP, Ertel A, Pestell RG. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Research. 2014 Jan 15; 74(2):508-19. PMCID: PMC3914674.
3. Casimiro, M.C., Ju, X., Gormley, M., Meng, H., Jiao, X., Katiyar, S., Crosariol, M., Chen, K., Wang, M., Quong, A.A., Lisanti MP, Ertel A, Pestell RG. Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells. Cancer Research, 2016 Jan 15;76(2):329-38. PMCID:PMC4715975.
4. Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG. v-Src oncogene induces Trop2 proteolytic cleavage. Cancer Res. 2016 Sep 15 PMID:27634768
5. Wu K, Katiyar S, Li A, Liu M, Ju X, Popov VM, Jiao X, Lisanti MP, Casola A, Pestell RG. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin- 8.. Proc Natl Acad Sci USA. 2008 May 13;105(19):6924-9. PMCID: PMC2374551.
6. Zhou J, Wang C, Wang Z, Dampier W, Wu K, Casimiro MC, Chepelev I, Popov VM, Quong A, Tozeren A, Zhao K, Lisanti MP, Pestell RG. Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci USA. 2010 Apr 13;107(15):6864-9. doi: 10.1073/pnas.1002746107. Epub 2010 Mar 29, PMCID: PMC2872468.
7. Chen K, Wu K, Wang L, Jiao X, Ju X, Li Z, Ertel A, Addya S, McCue P, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG. The endogenous Cell-Fate Factor Dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL Signaling Module. Cancer Research. 2015 2015 May 15;75(10):1992-2004. PMID:25769723.
8. Ozcan L, Ghorpade D, Cristina de Sozua J, Chen K, Bessler M, Bagloo M, Schrope B, Pestell RG, Tabas, I. Hepatocyte DACH1 is Increased in Obesity Via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. Cell Rep. 2016 May 26. un 7;15(10):2214-25 PMID:27239042
9. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000 Jul 7;275(27):20853- 60, PMCID: Identifier absent.
10. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Reutens, A.T., Albanese, C., Lisanti, M.P., Katzenellenbogen, B.S., Kato, S., Hopp, T., Fuqua, S.A., Lopez, G.N., Kushner, P.J., and Pestell, R.G., Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001 May 25; 276(21): p. 18375-83, PMCID: Identifier absent.
11. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Jänne OA, Pestell RG. Androgen Receptor Acetylation Governs Transactivation and MEKK1-Induced Apoptosis Without Effecting In Vitro Sumoylation and transrepression Function. Mol Cell Biol. 2002 May;22(10):3373-88.
12. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Jänne OA, Muratoglu S, Avantaggiati ML, Pestell RG. Acetylation of the androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003 Dec;23(23):8563-75, PMCID: PMC262657
13. Liu, M., Casimiro, M.C., Wang, C., Shirley, L.A., Jiao, X., Katiyar, S., Ju, X., Li, Z., Yu, Z., Zhou, J., Johnson, M., Fortina, P., Hyslop, T., Windle, J.J., and Pestell, R.G., p21CIP1 attenuates Ras- and c-Mycdependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA. 2009 Nov 10; 106(45): p. 19035-9. PMCID: PMC2776463.
14. Genander, M., Halford, M.M., Xu, N.J., Eriksson, M., Yu, Z., Qiu, Z., Martling, A., Greicius, G., Thakar, S., Catchpole, T., Chumley, M.J., Zdunek, S., Wang, C., Holm, T., Goff, S.P., Pettersson, S., Pestell, R.G., Henkemeyer, M., and Frisen, J., Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell. 2009 Nov 13; 139(4): p. 679-92, PMCID: PMC2786256.
15. Liu, M., Sakamaki, T., Casimiro, M., Willmarth, N., Quong, A., Ju, X., Ojeifo, J., Jiao, X., Yeow, W-S., Wang, C.,Katiyar, S., Shirley, L., Albanese, C., Joyce, D., Pestell, R.G. The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice via tumor stem cell expansion. Cancer Res. 2010 Dec 15;70(24):10464-10473.,k, PMCID: PMC3010731.
16. Jiao , X., Katiyar, S., Willmarth, N.E., Liu, M., Ma, X., Flomenberg, N., Lisanti, M.P., and Pestell, R.G., cJun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem. 2010 Mar 12; 285(11): p. 8218-26. PMCID: PMC2832973.
17. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK 3rd, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000 Jan;20(2):672-83. PMCID: PMC85165.
18. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, Cammer M, Chan A, Symons M, Stanley ER, Pestell RG. Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell. 2003 May;14(5):2005-15. Epub 2003 Feb 21. PMCID: PMC165093.
19. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA. 2006 Aug 1;103(31):11567-72. Epub 2006 Jul 24. PMCID: PMC1518800.
20. Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, Saria E, Papanikolaou A, Li Z, Wang C, Fortina P, Addya A, Tozeren A, Knudsen ES, Arnold A, Pestell RG. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest. 2012 Mar 1;122(3):833-43. doi: 10.1172/JCI60256. Epub 2012 Feb 6. PMCID: PMC3287228.
21. Polepallia S, George SM, Sri Vidyaa RV, Rodrigues GS, Ramachandra L, Chandrashekar R, Nayak D, Rao PPN, Pestell RG, Rao M. Role of UHRF1 in Malignancy and its Function as a Therapeutic Target for Molecular Docking Towards the SRA Domain. Intl J of Biochem & Cell Bio 2019 Sept Vol 144 105558. Link to article available on Elsevier at https://authors.elsevier.com/c/1ZIFA4qcwYO5Yj
